Effect of low-dose atropine on young premyopic and low-myopic children: atropine treatment of myopia (ATOM3) - a randomised control trial - PubMed
5 hours ago
- #pediatric-ophthalmology
- #atropine
- #myopia
- Study evaluated 0.01% atropine's effect on premyopic and low-myopic children aged 5-9.
- Randomized control trial with placebo vs. atropine groups over 2 years.
- Premyopic eyes showed no significant difference in progression between groups.
- Emmetropic eyes had less myopic shift with atropine (p=0.007).
- Low-myopia group showed trends toward less progression with atropine (p=0.066 for SER, p=0.062 for axial length).
- No significant difference in incident myopia rates between groups (42.6% placebo vs. 44.8% atropine).
- No notable side effects like near acuity loss or allergy differences between groups.
- Authors report mixed conflicts of interest, with some receiving funding/royalties.